What's Happening?
HeartBeam, Inc., a medical technology company, has announced the enrollment of the first patients in its ALIGN-ACS pilot study. This study aims to evaluate the HeartBeam System for heart attack detection outside traditional clinical settings. The first patients were
enrolled at the University Clinical Center of Serbia. The study is a significant step towards expanding the HeartBeam System's indication from arrhythmia to heart attack assessment. Heart attacks are a leading cause of death, with over 20 million at-risk patients in the U.S. The HeartBeam System allows patients to record a clinical-grade ECG at the onset of symptoms, potentially reducing the time to treatment. The study will enroll 100 patients with chest pain in emergency rooms, comparing results from a standard 12-lead ECG and the HeartBeam device.
Why It's Important?
The development of the HeartBeam System could revolutionize cardiac care by providing a reliable method for heart attack detection outside of hospitals. This technology addresses a critical gap, as many patients delay seeking care due to vague symptoms, increasing mortality and healthcare costs. By enabling early and accurate heart attack detection, the HeartBeam System could improve patient outcomes and reduce the burden on emergency services. The successful completion of this pilot study could lead to a multicenter pivotal study and future FDA approval, potentially unlocking a large market for heart attack assessment technology.
What's Next?
Following the pilot study, HeartBeam plans to conduct a multicenter pivotal study to support a future FDA submission. The company is also working on other initiatives, including the limited launch of its FDA-cleared arrhythmia assessment system and the development of a 12-lead ECG patch monitor. These efforts align with HeartBeam's long-term growth strategy to make cardiac care more accessible and intelligent. The results of the ALIGN-ACS study will inform the design of future studies and the potential expansion of the HeartBeam System's indications.
